[Biphosphonates and osteogenesis imperfecta in children].
Used for more than 10 years in addition to physiotherapy, orthopaedic surgery and rehabilitation, biphosphonate therapy has transformed the management of children with severe or moderate form of osteogenesis imperfecta. The authors of this article report indications, administration's way, duration and safety of biphosphonate therapy with uncertainties about persistence in skeleton for many years.
Gandon-Laloum
S
S
Service de chirurgie infantile, centre hospitalier régional universitaire de Caen, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France. gandonlaloum-s@chu-caen.fr
D015502:Absorptiometry, Photon; D000284:Administration, Oral; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017102:Fracture Healing / Q000187:drug effects; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008134:Long-Term Care; D010013:Osteogenesis Imperfecta / Q000188:drug therapy*; D000077268:Pamidronate; D026741:Physical Therapy Modalities
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate